Leonie A. Cluse

4.0k citations

21 papers · 2.4k indexed · 1 hit paper · h-index 18

Molecular Biology top 5%
Oncology top 5%
Immunology top 5%
Hematology top 5%
Cancer Research top 10%

Co-authors: Ricky W. Johnstone Andrew W. Roberts Adrian P. Wiegmans Warren S. Alexander Donald Metcalf Douglas J. Hilton Lynne Hartley Nicos A. Nicola
Topics: Histone Deacetylase Inhibitors Research (11 papers)Protein Degradation and Inhibitors (10 papers)Ubiquitin and proteasome pathways (4 papers)
Cited by: Oncology Immunology Hematology
Journals: Proceedings of the National Academy of Sciences Blood Immunity
Partner nations: Australia United States Austria

In The Last Decade

Leonie A. Cluse

21 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis

2007 538 citations Mai Nguyen, Richard Marcellus et al. Proceedings of the National Academy of Sciences profile →

Peers

Countries citing papers authored by Leonie A. Cluse

Since Specialization

Citations

This map shows the geographic impact of Leonie A. Cluse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leonie A. Cluse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leonie A. Cluse more than expected).

Fields of papers citing papers by Leonie A. Cluse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leonie A. Cluse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leonie A. Cluse. The network helps show where Leonie A. Cluse may publish in the future.

Co-authorship network of co-authors of Leonie A. Cluse

This figure shows the co-authorship network connecting the top 25 collaborators of Leonie A. Cluse. A scholar is included among the top collaborators of Leonie A. Cluse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leonie A. Cluse. Leonie A. Cluse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lipid-metabolism-focused CRISPR screens identify enzymes of the mevalonate pathway as essential for prostate cancer growth 2025 ·Cell Reports ·(unknown),Izabela Todorovski,Leonie A. Cluse,Stephin J. Vervoort,Renea A. Taylor,Matthew J. Watt	4
2	A Comprehensive Protocol Resource for Performing Pooled shRNA and CRISPR Screens 2018 ·Methods in molecular biology ·Leonie A. Cluse,Iva Nikolić,Deborah A. Knight,Piyush B. Madhamshettiwar,(unknown),(unknown),Timothy Semple,Gisela Mir Arnau,Jake Shortt,Ricky W. Johnstone,Kaylene J. Simpson	3
3	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1 2017 ·Cell Reports ·Simon J. Hogg,Stephin J. Vervoort,Sumit Deswal,Christopher J. Ott,Jason Li,Leonie A. Cluse,Paul A. Beavis,Phillip K. Darcy,Benjamin P. Martin,Andrew Spencer,(unknown),Irina Sadovnik,Karin Bauer,Peter Valent,James E. Bradner,Johannes Zuber,Jake Shortt,Ricky W. Johnstone	238
4	BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members 2016 ·Molecular Cancer Therapeutics ·Simon J. Hogg,Andrea Newbold,Stephin J. Vervoort,Leonie A. Cluse,Benjamin P. Martin,Gareth P. Gregory,Marcus Lefebure,Eva Vidacs,Richard W. Tothill,James E. Bradner,Jake Shortt,Ricky W. Johnstone	50
5	Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies 2015 ·Blood ·Geoffrey M. Matthews,Parinaz Mehdipour,Leonie A. Cluse,Katrina J. Falkenberg,Eric Wang,Mareike Roth,Fabio Santoro,Eva Vidacs,Kym L. Stanley,Colin M. House,James R. Rusche,Christopher R. Vakoc,Johannes Zuber,Saverio Minucci,Ricky W. Johnstone	46
6	Abstract 5533: RNAi-mediated depletion of histone deacetylases highlights the potential for isoform-specific inhibitors in B-cell lymphoma and acute myeloid leukemia 2014 ·Cancer Research ·Geoffrey M. Matthews,Leonie A. Cluse,Eric Wang,Mareike Roth,(unknown),Wenyan Miao,James R. Rusche,Johannes Zuber,Ricky W. Johnstone	1
7	An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors 2013 ·Cancer Research ·Alison C. West,Stephen R. Mattarollo,Jake Shortt,Leonie A. Cluse,Ailsa J. Christiansen,Mark J. Smyth,Ricky W. Johnstone	117
8	Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities 2013 ·Molecular Cancer Therapeutics ·Andrea Newbold,Geoffrey M. Matthews,Michael Bots,Leonie A. Cluse,Christopher J. Clarke,(unknown),Carleen Cullinane,Jessica E. Bolden,Ailsa J. Christiansen,Ross A. Dickins,Claudia Miccolo,Susanna Chiocca,Astrid M. Kral,Nicole Ozerova,Thomas A. Miller,Joey L. Methot,Victoria M. Richon,J. Paul Secrist,Saverio Minucci,Ricky W. Johnstone	40
9	HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses 2013 ·Cell Death and Disease ·(unknown),Wei Shi,Kacper Jankowski,(unknown),Leonie A. Cluse,Benjamin P. Martin,Karen L. MacKenzie,Gordon K. Smyth,Ricky W. Johnstone	150
10	A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance 2013 ·Blood ·Fabio Santoro,Oronza A. Botrugno,Roberto Dal Zuffo,Isabella Pallavicini,Geoffrey M. Matthews,Leonie A. Cluse,Iros Barozzi,Silvia Senese,Lorenzo Fornasari,Simona Moretti,Lucia Altucci,Pier Giuseppe Pelicci,Susanna Chiocca,Ricky W. Johnstone,Saverio Minucci	107
11	Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor 2012 ·Cell Death and Disease ·Lisa Lindqvist,Ingela B. Vikstrom,Jennifer M. Chambers,Kate McArthur,Mary Ann Anderson,Katya J. Henley,Lina Happo,Leonie A. Cluse,Ricky W. Johnstone,Andrew W. Roberts,Benjamin T. Kile,Ben A. Croker,Christopher J. Burns,Mark A. Rizzacasa,Andreas Strasser,David C.S. Huang	45
12	Deciphering the Molecular Events Necessary for Synergistic Tumor Cell Apoptosis Mediated by the Histone Deacetylase Inhibitor Vorinostat and the BH3 Mimetic ABT-737 2011 ·Cancer Research ·Adrian P. Wiegmans,Amber E. Alsop,Michael Bots,Leonie A. Cluse,Steven P. Williams,Kellie-Marie Banks,(unknown),Clare L. Scott,Anna Frenzel,Andreas Villunger,Ricky W. Johnstone	45
13	The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy 2009 ·Blood ·Leigh Ellis,Michael Bots,Ralph K. Lindemann,Jessica E. Bolden,Andrea Newbold,Leonie A. Cluse,Clare L. Scott,Andreas Strasser,Peter Atadja,Scott W. Lowe,Ricky W. Johnstone	99
14	Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin 2008 ·Molecular Cancer Therapeutics ·Andrea Newbold,Ralph K. Lindemann,Leonie A. Cluse,Kate F. Whitecross,Anthony E. Dear,Ricky W. Johnstone	56
15	Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors 2008 ·Blood ·Kate F. Whitecross,Amber E. Alsop,Leonie A. Cluse,Adrian P. Wiegmans,Kellie-Marie Banks,Claudia P. Coomans,Melissa J. Peart,Andrea Newbold,Ralph K. Lindemann,Ricky W. Johnstone	71
16	Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma 2007 ·Proceedings of the National Academy of Sciences ·Ralph K. Lindemann,Andrea Newbold,Kate F. Whitecross,Leonie A. Cluse,Ailsa J. Frew,Leigh Ellis,Steven P. Williams,Adrian P. Wiegmans,Anthony E. Dear,Clare L. Scott,Marc Pellegrini,Andrew H. Wei,Victoria M. Richon,Paul A. Marks,Scott W. Lowe,Mark J. Smyth,Ricky W. Johnstone	166
17	Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosisbreakdown → 2007 ·Proceedings of the National Academy of Sciences ·Mai Nguyen,Richard Marcellus,Anne Roulston,Mark Watson,Lucile Serfass,S.R. Murthy Madiraju,Daniel Goulet,Jean Viallet,Laurent Bélec,Xavier Billot,Stéphane Acoca,Enrico O. Purisima,Adrian P. Wiegmans,Leonie A. Cluse,Ricky W. Johnstone,Pierre Beauparlant,Gordon C. Shore	538
18	SOCS3 Is a Critical Physiological Negative Regulator of G-CSF Signaling and Emergency Granulopoiesis 2004 ·Immunity ·Ben A. Croker,Donald Metcalf,Lorraine Robb,Wei Wei,Sandra Mifsud,Ladina DiRago,Leonie A. Cluse,(unknown),Lynne Hartley,Emily Williams,Jian‐Guo Zhang,Douglas J. Hilton,Nicos A. Nicola,Warren S. Alexander,Andrew W. Roberts	234
19	The Rac2 Guanosine Triphosphatase Regulates B Lymphocyte Antigen Receptor Responses and Chemotaxis and Is Required for Establishment of B-1a and Marginal Zone B Lymphocytes 2002 ·The Journal of Immunology ·Ben A. Croker,David M. Tarlinton,Leonie A. Cluse,(unknown),Amanda Light,Feng‐Chun Yang,David A. Williams,Andrew W. Roberts	104
20	Rac2‐deficient mice display perturbed T‐cell distribution and chemotaxis, but only minor abnormalities in T_H1 responses 2002 ·Immunology and Cell Biology ·Ben A. Croker,Emanuela Handman,John D. Hayball,Tracey M. Baldwin,Valentina Voigt,Leonie A. Cluse,Feng‐Chun Yang,David A. Williams,Andrew W. Roberts	51

About Leonie A. Cluse

Leonie A. Cluse is a scholar working on Oncology, Hematology and Molecular Biology, having authored 21 papers that have together received 2.4k indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (11 papers), Protein Degradation and Inhibitors (10 papers) and Ubiquitin and proteasome pathways (4 papers). The work is most often cited by research in Oncology (884 citations), Immunology (638 citations) and Hematology (279 citations). Leonie A. Cluse has collaborated with scholars based in Australia, United States and Austria. Frequent co-authors include Ricky W. Johnstone, Andrew W. Roberts, Adrian P. Wiegmans, Warren S. Alexander, Donald Metcalf, Douglas J. Hilton, Lynne Hartley, Nicos A. Nicola, Andrea Newbold and Ben A. Croker. Their work appears in journals such as Proceedings of the National Academy of Sciences, Blood and Immunity.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact